<DOC>
	<DOCNO>NCT00759655</DOCNO>
	<brief_summary>This study investigate safety efficacy Xyntha ( moroctocog alfa ( AF-CC ) ) male patient less 6 year old . Annualized bleed rate physician / caregiver assessment responses treatment characterize . FVIII inhibitor level assess throughout study .</brief_summary>
	<brief_title>Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age</brief_title>
	<detailed_description>The study terminate 22 Sept 2009 due competition another Wyeth study similar patient population . The decision terminate trial base safety issue .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient le 6 year age moderately severe severe hemophilia A ( FVIII le equal 2 % ) . Treatment history le 50 exposure day prior recombinant plasmaderived FVIII replacement product . Not receive treatment HIV hepatitis infection , patient stable antiviral regimen time enrollment study . Presence bleed disorder addition hemophilia A. Inhibitor titer great equal 5 Bethesda Units ( BU ) screening . Treated immunomodulatory therapy screen period Treatment history 5 exposure day ( ED ) Xyntha . Known hypersensitivity hamster protein .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>hemophilia A</keyword>
	<keyword>Xyntha</keyword>
	<keyword>ReFacto</keyword>
	<keyword>moroctocog alfa</keyword>
	<keyword>bleed disorder</keyword>
</DOC>